Keytruda significantly improved PFS compared with brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma. - Merck Inc.
Related news and insights
Merck announced that the European Commission (EC) has approved an expanded label for Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult and pediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.
Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of an expanded label for Keytruda Merck’s anti-PD-1 therapy.
The FDA has approved Keytruda (pembrolizumab) as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL), and for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.